Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

3rd Immunotherapy of Cancer Conference (ITOC3)

21 - 23 Mar 2016

Munich Tumour Centre, Munich, Germany

Immunology highlights from the ITOC-3 conference

Prof Heinz Zwierzina - Innsbruck University, Innsbruck, Austria

Immunology highlights from the ITOC-3 conference ( Prof Heinz Zwierzina - Innsbruck University, Innsbruck, Austria )

Novel technologies for understanding the repertoire of tumour infiltrating T...

Prof Sine Reker Hadrup - Technical University of Denmark, Kongens Lyngby...

Novel technologies for understanding the repertoire of tumour infiltrating T cells in cancer ( Prof Sine Reker Hadrup - Technical University of Denmark, Kongens Lyngby, Denmark )

Targeting AFP in hepatocellular cancer

Dr Lisa Butterfield University of Pittsburgh, Pittsburgh, USA

Targeting AFP in hepatocellular cancer ( Dr Lisa Butterfield University of Pittsburgh, Pittsburgh, USA )

Combination of viroimmunotherapy with checkpoint inhibitors

Prof Alan Melcher - The Institute of Cancer Research and The Royal Marsden...

Combination of viroimmunotherapy with checkpoint inhibitors ( Prof Alan Melcher - The Institute of Cancer Research and The Royal Marsden Hospital, London, UK )

Is PD-L1 really a predictive biomarker?

Dr Paolo Ascierto - National Tumor Institute, Naples, Italy

Is PD-L1 really a predictive biomarker? ( Dr Paolo Ascierto - National Tumor Institute, Naples, Italy )

Patient perspective on immunotherapy and the ITOC-3 conference

Peter Trayhurn - Patient advocate

Patient perspective on immunotherapy and the ITOC-3 conference ( Peter Trayhurn - Patient advocate )

Hypoxia and its impact on the immune system

Dr Luigi Varesio - Giannina Gaslini Institute, Genova, Italy

Hypoxia and its impact on the immune system ( Dr Luigi Varesio - Giannina Gaslini Institute, Genova, Italy )

The role of microRNAs in modulation of the immune escape of tumors

Dr Barbara Seliger - Universitätsklinikum Halle , Saale, Germany

The role of microRNAs in modulation of the immune escape of tumors ( Dr Barbara Seliger - Universitätsklinikum Halle , Saale, Germany )

Reprogramming the cancer microenvironment with vaccine-based therapy

Prof Lei Zheng - John Hopkins Institute Baltimore, USA

Reprogramming the cancer microenvironment with vaccine-based therapy ( Prof Lei Zheng - John Hopkins Institute Baltimore, USA )

T cells expressing two additional receptors (TETARs) for the use in a multiple...

Dr Gerold Schuler - Universitätsklinikum, Erlangen, Germany

T cells expressing two additional receptors (TETARs) for the use in a multiple- hit immunotherapy ( Dr Gerold Schuler - Universitätsklinikum, Erlangen, Germany )

Biomarkers in t-cell therapy trials

Dr Jérôme Galon - Laboratory of Integrative Cancer Immunology, Paris, France

Biomarkers in t-cell therapy trials ( Dr Jérôme Galon - Laboratory of Integrative Cancer Immunology, Paris, France )

Immunotherapy and personalised medicine in review

Prof Paul Sondel - University of Wisconsin, Madison, USA

Immunotherapy and personalised medicine in review ( Prof Paul Sondel - University of Wisconsin, Madison, USA )

Rationale for combining immunotherapy with chemotherapy

Prof Angus Dalgleish - St. Georges University, London UK

Rationale for combining immunotherapy with chemotherapy ( Prof Angus Dalgleish - St. Georges University, London UK )

Targeting tumour vasculature by DNA vaccines

Dr Andrea Facciabene - University of Pennsylvania, Philadelphia, USA

Targeting tumour vasculature by DNA vaccines ( Dr Andrea Facciabene - University of Pennsylvania, Philadelphia, USA )

More from ecancer